A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
نویسندگان
چکیده
AML is characterized by excessive proliferation and infiltration of neoplastic cells of hematopoietic origin. AML occurs at a median age of 67 and will lead to an estimated 10,460 deaths in the United States in 2014. Therapy for AML has changed little in the last 30 years, and consists of an induction regimen of cytotoxic chemotherapy, followed by consolidation therapy and hematopoietic stem cell transplantation for appropriate patients. Unfortunately, outcomes from standard therapy are disappointing and most patients succumb to progressive disease or complications of therapy. AML is thought to arise in and be perpetuated by a small population of leukemic stem cells, characterized as CD34+, CD38-, that also express high levels of CD123, the interleukin-3 receptor alpha chain. The corresponding fraction of cells from normal bone marrow demonstrates low or undetectable expression of CD123. Based on these observations, targeting CD123 could be a promising strategy in the preferential ablation of AML cells. The DualAffinity Re-Targeting (DART) technology, is a proprietary antibody-based platform that has been designed to engage multiple targets with a single molecule. MGD006 is a novel CD123 × CD3 DART protein that targets CD123-positive cells for recognition and elimination by co-engagement of CD3-expressing T lymphocytes. In nonclinical studies, the ability of MGD006 to mediate redirected T cell killing of leukemic cells was demonstrated across multiple CD123-expressing target tumor cell lines, with efficacy generally correlating with the level of CD123 cell surface expression. Preclinical toxicology studies in cynomolgus monkeys demonstrated that MGD006 could be administered as a continuous intravenous infusion at doses achieving circulating MGD006 levels that exceeded those that demonstrated anti-leukemic activity in vitro, with acceptable safety. We have designed a Phase I dose-escalation study to investigate the safety, pharmacokinetics and preliminary activity of MDG006 in patients with relapsed/refractory AML. The study employs single patient cohorts starting at a dose equivalent to the minimum anticipated biological effect level (MABEL) of MGD006 to establish the starting dose for a subsequent standard 3+3 dose escalation to define the maximum tolerated dose of MGD006. This currently enrolling study represents the first clinical use of DART molecules in patients with cancer. ClinicalTrials.gov identifier NCT02152956.
منابع مشابه
Treatment of a Child with Refractory Acute Myeloid Leukemia with Humanized Anti-CD33 Monoclonal Antibody: A Case Report and Review of Drug Development
Background: The induction chemotherapy regimen for acute myeloid leukemia has evolved as once induction is completed patients progress through the consolidation phase and achieve remission in 76% of cases. For patients with relapsed or refractory disease, alternative chemotherapy agents are available. Monoclonal antibody therapy with biological agents, such as the immunotoxin gemtuzumab ozog...
متن کاملElacytarabine – A New Agent in the Treatment of Relapsed/Refractory Acute Myeloid Leukaemia
The prognosis for patients with relapsed acute myeloid leukaemia (AML) is poor, and effective treatments for this patient group remain a substantially unmet clinical need. Elacytarabine is a promising new cytotoxic nucleoside agent made by an esterification reaction between cytarabine and elaidic acid, currently in development for use in the treatment of relapsed/refractory AML. Unlike cytarabi...
متن کاملEffects of Dietary Honey and Ardeh Combination on Chemotherapy- Induced Gastrointestinal and Infectious Complications in Patients with Acute Myeloid Leukemia: A Double-Blind Randomized Clinical Trial
We aimed to investigate the effects of dietary combination of honey and Ardeh on chemotherapy-induced complications in patients with acute myeloid leukemia (AML).A total of 107 AML patients who underwent chemotherapy for at least 30 consecutive days were recruited to this double-blind randomized placebo-controlled clinical-trial which was conducted in the Imam Reza and Ghaem teaching hospitals ...
متن کاملTargeted Alpha-Particle Immunotherapy with Bismuth-213 and Actinium-225 for Acute Myeloid Leukemia
Lintuzumab, a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest activity against acute myeloid leukemia (AML). To increase the antibody’s potency yet avoid nonspecific cytotoxicity seen with -emitting isotopes, lintuzumab was conjugated to the -emitters bismuth-213 (213Bi) and actinium-225 (225Ac). The 46-minute half-life of 213Bi limits its widespread use. Therefore...
متن کاملPrognostic Value of EVI1 Expression in Pediatric Acute Myeloid Leukemia: A Systematic Review
Acute myeloid leukemia (AML) as a distortion of blood cells involves the differentiation of hematopoietic stem cells. Several studies established the irregular overexpression of specific genes is a common finding in patients with AML. The ectopic viral integration site-1 (EVI1) gene is a proto-oncogene subject to alternative splicing, and encodes a zinc-finger protein that acts as a tr...
متن کامل